R&D News | pharmaphorum

News

RNAi biotech City hauls in $200m in upsized IPO

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

News

AI in drug discovery & development: News watch, October 2026

Recent news in biopharma AI include a $1.5bn partnership between AstraZeneca and insitro, plus news from Iambic, DaltonTx, NVIDIA, and Chai Discovery.

News

GLP-1 drugs linked to reduced acute schizophrenia episodes

The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.

News

Could OMass become the UK's 'big biotech' company?

UK-based OMass Therapeutics' ambition to join the 'big biotech' ranks has been bolstered by an impressive $310m third-round financing.

News

GSK planning 1,200 job cuts in Belgium, says paper

GSK is said to be preparing to cut around 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels.

News

Zealand forges obesity alliance with AI specialist Generate

Zealand has added another strand to its programme of weight-loss drug development, linking with AI player Generate on multispecific protein therapies.

RNAi biotech City hauls in $200m in upsized IPO

AI in drug discovery & development: News watch, October 2026

GLP-1 drugs linked to reduced acute schizophrenia episodes

Could OMass become the UK's 'big biotech' company?

GSK planning 1,200 job cuts in Belgium, says paper

Zealand forges obesity alliance with AI specialist Generate

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks